loader2
Partner With Us NRI

Glaxosmithkline Pharmaceuticals Ltd share Price Today

Company details

1,890.45
1,962.35
1,227.00
2,524.00
6M Return 27.62%
1Y Return 53.46%
Mkt Cap.(Cr) 32,976.57
Volume 120,032
Div Yield 1.65%
OI
-
OI Chg %
-
Volume 120,032

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Glaxosmithkline Pharmaceuticals Ltd shares SWOT Analysis

Strengths (3)

  • Company with No Debt
  • Company with Zero Promoter Pledge
  • FII / FPI or Institutions increasing their shareholding

Weakness (3)

  • MFs decreased their shareholding last quarter
  • Declining Net Cash Flow : Companies not able to generate net cash
  • Major fall in TTM Net Profit

Opportunity (0)

Data not found

Threats (3)

  • High PE (PE > 40)
  • Increasing Trend in Non-Core Income
  • RSI indicating price weakness

Resistance and support

R1 1,975.8
R2 2,005.0
R3 2,047.7
Pivot

1,933.13

S1 1,903.9
S2 1,861.2
S3 1,832.0
EMA SMA
2,010.8
2,057.1
1,967.2
1,795.4
2,017.5
2,163.7
1,967.4
1,708.9
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
ISHARES CORE MSCI EMERGING MARKETS ETF Block Purchase 2022-10-17 1378.65 80615 BSE
ISHARES MSCI INDIA SMALL-CAP ETF Block Purchase 2022-10-17 1378.65 11841 BSE
ISHARES CORE EMERGING MARKETS MAURITIUS CO Block Sell 2022-10-17 1378.65 80615 BSE
Name Category Shares
GLAXO GROUP LIMITED PROMOTER 35.99%
GLAXOSMITHKLINE PTE LIMITED PROMOTER 28.1%
ESKAYLAB LIMITED PROMOTER 6.94%
BURROUGHS WELLCOME INTERNATIONAL LIMITED PROMOTER 3.97%

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Glaxosmithkline Pharmaceuticals Ltd Stocks COMPARISON

Financials( in Cr) Glaxosmithkline Pharmaceuticals Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Dr Reddys Laboratories Ltd Zydus Lifesciences Ltd
Price 1,946.60 1,620.55 1,496.95 6,157.90 1,007.35
% Change 3.55 1.02 2.30 1.88 0.77
Mcap Cr 32,976.57 388,824.23 120,856.26 102,719.31 101,964.37
Revenue TTM Cr 3,251.72 43,885.68 15,790.60 24,669.70 17,237.40
Net Profit TTM Cr 610.69 8,560.84 2,513.47 4,507.30 1,997.30
PE TTM 51.32 41.45 30.52 19.64 30.51
1 Year Return 53.46 64.78 68.33 37.28 109.04
ROCE 33.92 16.79 14.76 25.99 16.25
ROE 27.73 16.46 10.66 21.21 14.05
INSIDER & INSTITUIONAL ACTIVITY

Equity Capital: 1,741.28 Cr FV: 10.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 29,068.81 33,709.58
LAST 3M 68,518.10 30,558.15
LAST 6M 130,081.93 64,349.19
LAST 12M 189,941.35 208,211.24
GlaxoSmithKline Pharmaceuticals Limited - Trading Window

Mar 26, 2024 l NSE Announcement

GlaxoSmithKline Pharmaceuticals Limited - Updates

Mar 22, 2024 l NSE Announcement

Date Action Type Ratio
Jun 30, 2023 Dividend 320
Jul 07, 2022 Dividend 600
Jul 07, 2022 Dividend 300

Glaxosmithkline Pharmaceuticals Ltd Information

Stock PE (TTM)
51.32
Promoter Holding
75%
Book Value
90.8791
ROCE
33.92%
ROE
27.73%
Description
  • GlaxoSmithKline Pharmaceuticals Ltd is in the Pharmaceuticals sector is having a market capitalization worth Rs. 25,676.02 crores, it is incorporated in the year 1924. It has reported consolidated sales of Rs. 789.99 crores in June 2021. The company is listed on the Bombay Stock Exchange (BSE) with the code 500660, and also listed on the National Stock Exchange (NSE) with the code GLAXO.

    GlaxoSmithKline Pharmaceuticals is one of the leading manufacturers of pharmaceuticals and vaccines in India. GSK entered the Indian market under the name of H J Foster & Co Ltd. The company generated 76% of its revenue from the selling and distribution of pharmaceuticals while the vaccine segment generated 24% of its revenue. 5 of the brands marketed by GSK feature in the India Pharmaceutical Market. These brands are (i) Augmentin, (ii) Betnovate, (iii) Calpol, (iv) Ceftum, and (v) Synflorix. GSK has a developed a team of over 5,000 employees spread across the country. GSK has also established two global Research & Development centers in the country. The promoters of the company own 75.0% of the stake in the company, Foreign Institutional Investors (FII) own 1.61% of the stake, Domestic Institutional Investors (DII) own 10.92%, and others (such as public & retail investors) hold the balance of 12.47%.

    In June 2021, quarterly net revenue was Rs. 773.46 crores, which has increased by approximately 19.24 % from Rs. 648.65 crores for the April-June 2020 quarter. The quarterly net profit in June 2021 was Rs. 120.4 crores, which has improved sharply and increased by nearly 8.51% from a net profit of Rs. 110.96 crores in June 2020. In June 2021, the reported operating profit was at Rs. 645.05 crores, which is increased by 10.95% as compared to an operating profit of Rs. 581.39 crores for the quarter ending in June 2020. From an EPS of Rs. 6.55 in June 2020, the EPS of Glaxosmithkline Pharmaceuticals Ltd has improved and reached an EPS of Rs. 7.11 per share in June 2021. GLAXO's stock closed at Rs. 1,515.65 on 27th August’2021 (NSE). GlaxoSmithKline Pharmaceuticals Ltd has returned 3.77% in the last six months and returned 5.18% negatively in the previous year.

Registered Address

GSK House, Dr Annie Besant Road Worli, Mumbai, Maharashtra, 400030

Tel : 91-022-24959595
Email : askus:gsk.com; ajay.a.nadkarni:gsk.com
Website : http://www.gsk-india.com
Registrar

Karvy Computershare Pvt Ltd

AGM Date (Month) : Jul
Face Value Equity Shares : 10
Market Lot Equity Shares : 1
BSE Code : 500660
NSE Code : GLAXO
Book Closure Date (Month) :
BSE Group : A
ISIN : INE159A01016

FAQ’s on Glaxosmithkline Pharmaceuticals Ltd Shares

You can buy Glaxosmithkline Pharmaceuticals Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Glaxosmithkline Pharmaceuticals Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Mar 28, 2024 03:58 PM the closing price of Glaxosmithkline Pharmaceuticals Ltd was ₹ 1,946.60.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Mar 28, 2024 03:58 PM, the market cap of Glaxosmithkline Pharmaceuticals Ltd stood at ₹ 32,976.57.

The latest PE ratio of Glaxosmithkline Pharmaceuticals Ltd as of Mar 28, 2024 03:58 PM is 51.32

The latest PB ratio of Glaxosmithkline Pharmaceuticals Ltd as of Mar 28, 2024 03:58 PM is 0.05

The 52-week high of Glaxosmithkline Pharmaceuticals Ltd share price is ₹ 2,524.00 while the 52-week low is ₹ 1,227.00

Download Our

Download App
market app